☆ 4.6 Editorial Material

Should we prefer biologics over nonbiological agents in psoriasis?

BRITISH JOURNAL OF DERMATOLOGY (2023)

Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Oras A. Alabas et al.

Summary: The aim of this study was to determine the real-world effectiveness and survival of methotrexate (MTX) and adalimumab (ADA) in patients with moderate-to-severe psoriasis registered in BADBIR. The study found that patients on ADA were twice as likely to be clear or nearly clear of psoriasis and were less likely to discontinue their medication than patients on MTX.

BRITISH JOURNAL OF DERMATOLOGY (2023)

添加到收藏夹

Article Dermatology

Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study

K. Schaekel et al.

Summary: This study evaluated the efficacy of Guselkumab in patients with psoriasis and found that early intervention led to better clinical outcomes. It also investigated the relationship between disease duration, serum biomarkers, and clinical response.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

Ahmed I. Mourad et al.

Summary: Drug survival studies in psoriasis assessed the comparative effectiveness of biologics like ustekinumab, adalimumab, etanercept, infliximab, secukinumab, and ixekizumab in real-world settings. Results showed ustekinumab had the longest persistence, with adalimumab outperforming etanercept and infliximab at 5 years. The estimated pooled 2- and 5-year drug survival rates can serve as a useful tool for patient communication and clinical decision-making.

FRONTIERS IN MEDICINE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Patent expiry dates for biologicals: 2018 update

Michelle Derbyshire et al.

GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2019)

添加到收藏夹

Article Dermatology

Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study

L. Iversen et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)

添加到收藏夹

Should we prefer biologics over nonbiological agents in psoriasis?

相关参考文献

Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study

Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

Patent expiry dates for biologicals: 2018 update

Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study

导出引文

分享论文